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 ■ INTRODUCTION
Chronic pancreatic involvement in patients diagnosed with 
Crohn’s disease (CD) has been the focus of studies in recent years 
(1-7). Medications, primary sclerosing cholangitis, inflammatory 
involvement of the duodenum and autoimmune pancreatitis (AIP) 
are all well-established causes of pancreatitis in this population (8-
12). Studies on this topic are limited and extremely heterogeneous, 
mainly because there is no established consensus method to study the 
pancreas. The prevalence of this combination (CD and pancreatitis) 
ranges from 1.2% to 58% depending on the population studied and 
the method of pancreatic evaluation employed (5,6,13-18).
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OBJECTIVES: We aimed to evaluate the incidence of pancreatic alterations in Crohn’s disease using endoscopic 
ultrasound (EUS) and to correlate the number of alterations with current clinical data.
METHODS: Patients diagnosed with Crohn’s disease (n=51) were examined using EUS, and 11 variables were 
analyzed. A control group consisted of patients with no history of pancreatic disease or Crohn’s disease. Patients 
presenting with three or more alterations underwent magnetic resonance imaging (MRI). Pancreatic function was 
determined using a fecal elastase assay.
RESULTS: Two of the 51 patients (3.9%) presented with four EUS alterations, 3 (5.9%) presented with three, 
11 (21.5%) presented with two, and 13 (25.5%) presented with one; in the control group, only 16% presented 
with one EUS alteration (p<0.001). Parenchymal abnormalities accounted for 39 of the EUS findings, and ductal 
abnormalities accounted for 11. Pancreatic lesions were not detected by MRI. Low fecal elastase levels were 
observed in 4 patients, none of whom presented with significant pancreatic alterations after undergoing EUS. Ileal 
involvement was predictive of the number of EUS alterations.
CONCLUSION: A higher incidence of pancreatic abnormalities was found in patients with Crohn’s disease than in 
individuals in the control group. The majority of these abnormalities are related to parenchymal alterations. In this 
group of patients, future studies should be conducted to determine whether such morphological abnormalities could 
evolve to induce exocrine or endocrine pancreatic insufficiency and, if so, identify the risk factors and determine 
which patients should undergo EUS.
KEYWORDS: Crohn’s Disease; Pancreatitis; Pancreatic Exocrine Insufficiency; Endosonography; 
Cholangiopancreatography.
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Postmortem studies of patients diagnosed with CD that did 
not present with pancreatic symptoms have found pancreatic 
fibrosis (38% of cases) distributed in the interlobular and 
periductal areas, as well as acinar dilation (31% of cases) 
(15,19). Pancreatic lesions are believed to result from the 
formation of immunocomplexes and autoantibodies against the 
pancreas, which are known as glycoprotein 2 (GP2) –specific 
pancreatic autoantibodies (PAB) (1,9,20,21). Furthermore, 
the formation of epithelioid granulomas has been described in 
patients with CD (14,22). Epithelial cells of the gastrointestinal 
tract and pancreatic tissue may share similar target molecular 
or cellular structures vulnerable to injuries (23), as observed 
in animal studies where there was overexpression of abnormal 
proinflammatory hypoglycosylated mucinin, both in the colonic 
epithelium of patients with inflammatory bowel disease (IBD) 
and in the pancreatic ductal epithelium (24).
Endoscopic retrograde cholangiopancreatography (ERCP) 
is considered the gold standard for the study of pancreatic 
morphology. However, in addition to morbidity risks, this method 
evaluates only the pancreatic ducts, providing no information on 
the conditions of the pancreatic parenchyma (25,26). Endoscopic 
ultrasound (EUS) is more sensitive, is safer, evaluates both the 
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parenchyma and the pancreatic ducts and correlates strongly with 
histological findings (27-33).
Although there is considerable agreement between EUS and 
ERCP when the EUS results are either normal or when they reveal 
moderate to severe pancreatitis, many patients have presented 
with mild EUS alterations but have normal ERCP results (34-37). 
Elderly patients, obese patients, and patients with diabetes 
mellitus, as well as patients who consume excessive amounts 
of alcohol, present with EUS alterations in the pancreas that are 
unrelated to disease. With the exception of these patients, studies 
have hypothesized that patients presenting with altered EUS but 
normal ERCP results are suffering from pancreatitis in its initial 
stages because, pathophysiologically, parenchymatous alterations 
precede ductal alterations in the necrosis-fibrosis sequence in the 
development of chronic pancreatitis (38). To increase the specificity 
of EUS, some authors have suggested that the pancreas should be 
considered normal if only one or two endoscopic criteria are met, 
whereas a pancreas displaying three or more of these criteria should 
be considered abnormal (30,31,34,39).
Exocrine pancreatic insufficiency has been reported in 
IBD in 18 to 80% of cases, as measured by the fecal elastase, 
paraminobenzoic acid (PABA), amylase, lipase meal and 
secretin-cerulein tests. (7,14,40). Fecal elastase is considered 
the gold standard among noninvasive tests of pancreatic function 
(41). Although the results obtained by this method are in 
agreement with the tests of pancreatic function that use duodenal 
intubation (42), it can yield false positives for intestinal diseases 
(because of dilution and consequent reduction in enzymatic 
concentration) and displays low sensitivity to mild or moderate 
pancreatitis (38,41,43-46).
In the present study, we sought to evaluate the incidence 
of pancreatic alterations identified using EUS in patients with 
established CD and correlate these results with factors such as 
duration of the disease, disease site, medication use, and level of 
disease activity. To correlate these morphological alterations with 
pancreatic exocrine function, we decided to measure fecal elastase 
levels. We also compared the EUS findings with magnetic resonance 
cholangiography (MRCP) findings. To the best of our knowledge, 
this study is the first to analyze pancreatic EUS abnormalities in CD 
patients, which is an important tool to detect preliminary alterations 
of the pancreas.
 ■ MATERIALS AND METHODS
Fifty-one patients between 18 and 60 years of age who were 
diagnosed with CD on the basis of clinical, radiological, endoscopic, 
or anatomopathological criteria were selected to participate in this 
prospective study.
Patients previously diagnosed with pancreatitis, sclerosing 
cholangitis, or diabetes mellitus; patients who were obese; or 
patients who had previous gastrectomy or gastro-jejunal bypass were 
excluded, as were those who consumed more than 30 g of alcohol/
day or who were active smokers (less than 5 years after quitting).
Data regarding age, gender, elapsed time since disease onset, CD 
activity index (47), anatomical location of the disease, extraintestinal 
manifestations, and surgical history, as well as prior and current use 
of medications, were collected. Serum levels of amylase and lipase 
were also determined for all of the patients studied.
Endoscopic ultrasound
EUS was conducted by the endoscopy team at the Hospital das 
Clínicas using a 7.5 MHz linear transducer (GFUCT 140; Olympus, 
Hamburg, Germany) under propofol sedation. The pancreas was 
evaluated by 2placing the transducer in the duodenal bulb (for 
visualizing head of the pancreas), second and third part of the 
duodenum (uncinated process) and over the stomach (body and 
pancreatic tail). The diameter of the pancreatic duct was measured 
at the confluence of the splenic vein and the upper mesenteric vein.
As shown in Figure 1, pancreatic alterations identified through 
EUS were classified as either parenchymatous or ductal (28,29,47). 
Three or more of these criteria were considered abnormal. Twenty 
patients in the control group who did not have pancreatic disease, 
biliary disease, or a history of inflammatory intestinal disease also 
underwent EUS (EUS control group).
Magnetic resonance cholangiography
Patients who presented with three or more EUS alterations 
suggestive of chronic pancreatic also underwent MRCP to determine 
whether there was a correlation between these two methods.
A 1.5 T magnetic resonance imaging (MRI) scanner was used 
(Sigma; GE Medical Systems, Milwaukee, Wisconsin, USA). 
The sequence carried out for each pass was as follows: axial 
T2-weighted fast spin-echo; axial spoiled gradient-recalled dual-
echo (in-phase and out-phase); coronal single-shot fast spin-echo 
with fat saturation; axial spoiled gradient-recalled echo with fat 
saturation; and axial dynamic spoiled gradient-recalled echo 
(arterial and portal).
Sequences were obtained during apnea with the cooperation of 
the patients who had fasted for 8 h prior. No type of contrast agent 
or sedation was administered. The sequences were performed in 
three spatial planes and, occasionally, in oblique planes. Images 
were projected at maximum intensity and analyzed using multiplane 
reconstruction at a workstation.
Fecal elastase
Pancreatic fecal elastase levels were determined using 
an enzyme-linked immunosorbent assay (ELISA) that used 
two polyclonal antibodies that recognize different epitopes 
at defined sequences of human pancreatic elastase according 
to the manufacturer´s instructions (BIOSERV Diagnostics, 
Rostok, Germany).
Samples were collected from 39 patients in the CD group. 
Samples were collected from 10 patients with chronic alcoholic 
pancreatitis (chronic pancreatitis group) and from 10 individuals 
without any clinical symptoms, radiological findings, or laboratory 
test results indicative of pancreatic disease (fecal elastase control 
group) to serve as positive and negative controls. All tests were 
carried out in duplicate.
Figure 1 – Endoscopic alterations suggestive of chronic 
pancreatitis.
Parenchymatous alterations Ductal alterations
Hyperechoic foci Dilatation
Lobularity Irregularities
Cysts
Hyperechoic margins of the 
principal duct
Calcifications Visible lateral branches
Hyperechoic lesions
Atrophy
Heterogeneous echoic pattern
3Pancreatic EUS findings in Crohn’s disease
Malluta E F et al.
CLINICS 2019;74:e853
Ethical aspects
The present study was approved by the Ethics in Research 
committee of the University of Sao Paulo Medicine School - 
Hospital das Clínicas. All patients gave written informed consent.
Statistical analysis
Statistical analysis was carried out using the Statistical 
Package for the Social Sciences (SPSS) program for Windows, 
version 10.0. Comparisons between patients with CD and the 
EUS control group were made using Student’s t-test. One-way 
ANOVA was used for comparisons among the CD group, chronic 
pancreatitis group and fecal elastase control group. For analysis 
of the correlation between different variables in the CD group, 
Spearman’s correlation coefficient was used. Values of p<0.050 
were considered statistically significant.
 ■ RESULTS
Of the 51 patients examined by EUS, 28 (56%) were female. 
The mean age was 38 years (range, 18–59 years). The mean elapsed 
time since diagnosis of the disease was 7 years (range, 1–25 
years), and the mean CD activity index was 102 (range, 20-419). 
The majority of patients presented with ileal involvement, either 
isolated (47% of cases) or in combination with colonic involvement 
(approximately 37% of cases). In 8% of the cases, only the upper 
gastrointestinal tract was affected.
Approximately 40% of the patients currently presented 
with or had a history of enteral fistulas, and 20% presented with 
stenosing CD. Extraintestinal manifestations of the disease (mostly 
osteoarticular) were observed in 58% of the patients. With respect 
to current and previous medication use, 56% reported having used 
azathioprine (Table 1).
Although none of the patients presented with an elevated level 
of serum lipase, 9% presented with an increase in serum amylase 
(less than 1.5 times higher than the upper limit of normal).
Endoscopic ultrasound
All 51 patients underwent EUS examination. According 
to the EUS results, 2 patients (3.9%) presented with four of the 
abnormalities suggestive of chronic pancreatic disease (as described 
in the Methods section), and three patients (5.9%) presented with 
three abnormalities (Table 2).
The prevalence of parenchymatous abnormalities (39 out of 51) 
was significantly higher than that of ductal abnormalities (11 out of 
51) among patients with CD (Table 3).
Table 1 – Epidemiological features of Crohn’s disease patients.
Variable
Gender, n (%)
Female 28 (55)
Male 23 (45)
Age (years), mean ± SD 38.5 ± 10.4
Years since diagnosis, mean ± SD 7.2 ± 5.7
Azathioprine use, n (%)
Yes 29 (57)
No 5 (10)
No data 17 (33)
Amylase, mean ± SD 74.7 ± 28.7
Lipase, mean ± SD 32.7 ± 11.6
Extraintestinal manifestations, n (%)
Yes 30 (59)
No 16 (31)
No data 5 (10)
Crohn’s disease activity index, mean ± SD 102.0 ± 80.0
Anatomical location, n (%)
Ileum 23 (45)
Colon 6 (12)
Ileum-colon 16 (31)
Upper gastrointestinal tract 6 (12)
Anorectal 0 (0)
Disease presentation, n (%)
Stenosing 12 (23)
Fistulizing 21 (41)
Inflammatory 8 (16)
SD: standard deviation.
Table 2 – Endoscopic ultrasound findings*.
EUS alterations (n) Crohn’s disease, n (%) Controls, n (%)
4 2 (3.9) 0
3 3 (5.9) 0
2 11 (21.5) 0
1 13 (25.5) 3 (16)
*Patients with Crohn’s disease vs controls, p<0.001.
EUS:, endoscopic ultrasound.
Table 3 – Endoscopic ultrasound findings of parenchymatous 
and ductal alterations.
Alteration Crohn’s disease (%) Controls (%)
Parenchyma
Hyperechoic foci 15 (35) 3 (100)
Hyperechoic lesions 11 (21) 0
Globular external margins 4 (7) 0
Lobularity 1 (2) 0
Cysts 0 0
Calcification 0 0
Atrophy 2 (3) 0
Heterogeneous echoic pattern 6 (11) 0
Ductal
Principal duct dilatation 0 0
Secondary duct dilatation 0 0
Ductal irregularity 0 0
Hyperechoic ductal margins 11 (21) 0
Total 50 (100) 3 (100)
*Patients with Crohn’s disease vs controls, p<0.001.
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Of the control group, 3 patients (16%) presented with one 
alteration by EUS examination. The remaining control group 
patients presented with no abnormalities on the EUS (Table 2). 
The difference between the two groups was statistically significant 
(p<0.001). The only variable that correlated with the EUS data was 
the ileal location of the disease (p=0.040).
Magnetic resonance cholangiography
The patients presenting with three or more abnormalities by 
EUS were examined by MCRP. One of these patients died prior to 
MCRP. The cause of death was unrelated to CD or to the tests that 
were carried out in this study.
None of the patients who were examined by MCRP presented 
with any abnormalities.
Fecal elastase
The mean levels of fecal elastase (μg of elastase/g of feces) 
for each group were as follows: 450 μg/g for the CD group, 487 
μg/g for the control group, and 125 μg/g for the chronic pancreatitis 
group. No significant difference was observed between the CD 
group and the fecal elastase control group. There was no correlation 
between the CD activity index and the level of fecal elastase.
Four patients (10%) presented with results suggestive of 
exocrine pancreatic insufficiency (a fecal elastase value <200 μg/g 
of feces), and 2 of these patients were classified as having severe 
exocrine insufficiency. For EUS, none of these 4 patients presented 
with any abnormalities in pancreatic morphology. In contrast, 
patients with three or more EUS abnormalities presented fecal 
elastase levels that were within the normal range. In addition, no 
correlation was found between the levels of fecal elastase and the 
epidemiological characteristics of the population.
 ■ DISCUSSION
There is a growing number of studies linking IBD and 
pancreatitis, as shown in a recent review by Srinath et al. (48). The 
main subtypes are acute pancreatitis, chronic pancreatitis, AIP and 
asymptomatic abnormalities. The present study shows that 9.8% of 
the patients with CD presented with pancreatic involvement (three 
or more abnormalities) in morphological evaluations using EUS, 
predominantly in patients with ileal involvement. In other words, 
ileal involvement was predictive of the number of EUS alterations.
This finding is in line with those published in 2012 by 
Pavlidis et al. (21), showing that ileal inflammation may trigger the 
development of GP2-specific PAB in patients with CD. This protein 
is present on the apical surface of microfold (M) intestinal cells 
located in the ileum but not in colonic cells, which explains the 
close relation between higher positive rates in CD (almost 40%) 
versus fewer than 8% in UC.
Our findings are also in agreement with other studies on the 
morphological evaluation of the pancreas in patients with CD. In a 
retrospective study involving 255 patients with CD, the prevalence 
of pancreatic abnormalities in individuals presenting with no signs 
or symptoms of chronic pancreatitis on abdominal ultrasound, 
computed tomography, or ERCP was 6.3% (18). In a prospective 
study evaluating pancreatic morphology in patients with CD, Heikius 
et al. (16) used ERCP as a diagnostic tool. The authors observed 
abnormalities suggestive of chronic pancreatitis in 4 (8.7%) out of 
46 ERCP procedures performed. In a prospective study, Barthet et 
al. (7) found a 30% prevalence of pancreatic insufficiency among 
IBD patients with no previous history of pancreatopathy and a 50% 
prevalence among patients with previous symptoms. In that study, 
patients were evaluated by pancreato-MRI and exocrine function by 
fecal elastase test, amylase, lipase, C-reactive protein, pancreatitis 
associated protein (PAP), IgG4 and PAB.
In our study, the higher prevalence of pancreatic 
abnormalities (9.8% of the patients presented with three or 
more EUS abnormalities) can be explained by differences in the 
morphological evaluation method. Importantly, three or more 
positive EUS signs are suggestive of chronic pancreatopathy 
instead of chronic pancreatitis. The sensitivity of EUS in evaluating 
the pancreatic duct and the parenchyma, which is crucial to the 
early detection of chronic pancreatitis, appears to be greater than 
that of ERCP (38,49). For the evaluation of pancreatic diseases 
in patients with CD, EUS is the most rational choice because 
pancreatic abnormalities in this situation are predominantly 
parenchymatous, as has been shown in anatomopathological 
studies (15,50). By evaluating our patients endoscopically, 
we found more parenchymatous abnormalities predominated 
than ductal abnormalities, accounting for 39 and 11 findings, 
respectively. Based on these results, we may presume that CD 
patients have pancreatic abnormalities similar to those of patients 
with obesity, diabetes and alcohol intake, and the vast majority are 
asymptomatic. However, our results are from only one observer. 
We could not integrate interobserver agreement into the study, 
which would have led to more reliable results. Additionally, the 
patients who had EUS alterations underwent MRCP without 
any contrast agent. The use of gadolinium could provide more 
information on minimal parenchymal changes. All patients in the 
study who submitted to this procedure had no abnormalities.
We identified pancreatic insufficiency in 10% of patients with 
CD by fecal elastase level determination, although all 4 patients 
who had values below the threshold of 200 μg/g did not have any 
ultrasonographic changes, suggesting that some patients with CD 
might have a functional pancreatic insufficiency not related to 
morphologic changes in the gland. This finding is in agreement with 
previous results obtained for patients with idiopathic pancreatitis 
(51), as well as for patients with mild or moderate pancreatitis 
(35,52–54). Lindstrom et al. analyzed patients with inflammatory 
intestinal disease and primary sclerosing cholangitis (55). The 
authors observed primary abnormalities in morphology rather than 
in pancreatic function. The fecal elastase test has an insufficient 
sensitivity (68–77%) and is inappropriate to demonstrate early 
chronic pancreatitis with a cut-off value of 200 g/g stool (45,56-58). 
The sensitivity of the fecal elastase test is closely related to the 
severity of pancreatic insufficiency (45,57).
Only four previous studies have analyzed exocrine 
pancreatic function in patients with CD (5,6,16,17). Among the 
patients studied, the proportion presenting with a decrease in 
pancreatic function ranged from 4.2% to 58%. Such variation 
occurred due to the differences among the methods used to 
evaluate pancreatic function. Among the studies employing 
invasive tests (e.g., those involving duodenal intubation), one 
used a secretin test to evaluate pancreatic function in 54 patients, 
2 (4.2%) of which presented with abnormalities (16). Angelini 
et al. used the secretin-cerulein test in 17 patients with CD (5). 
The authors observed that in the duodenal aspirate, 35% of the 
patients presented with a decrease in the secretion of enzymes 
and bicarbonate, whereas 58% presented with a decrease only 
in the concentration of lipase. Using the Lundh meal test, 
Hegnohj et al. noted a significant decrease in the concentration 
of amylase and lipase in the duodenal aspirate of 143 patients 
with CD and that the decrease was significantly greater in 
patients presenting with extensive ileal involvement (6). Seibold 
et al. used noninvasive methods (fluorescein dilaurate and fecal 
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chymotrypsin) to evaluate pancreatic function in patients with 
CD (17). The authors found that the prevalence of impaired 
pancreatic function was approximately 15%, regardless of the 
method employed and that such impairment was more common 
in patients with autoantibodies against the exocrine pancreas.
AIP was recently described (59). AIP is characterized by serum 
IgG4 elevation associated with predominantly lymphoplasmocytic 
inflammatory infiltrate and is accompanied by pancreatic fibrosis, 
thereby provoking pancreatic insufficiency (60-62). AIP can be 
associated with inflammatory intestinal disease in 5% to 22% of 
cases (12,20,60,63), and an elevation of IgG4 was observed in 
colonic biopsies from IBD patients even without pancreatic disease 
(64). The most common EUS findings are a focal or diffuse increase 
in the size of the pancreas, together with diffusely or focally 
hypoechoic pancreatic parenchyma (65). In a recent study, Hoki 
et al. concluded that the Sahai criteria (34) for chronic pancreatitis 
are inadequate for the evaluation of AIP, where the average score 
was only 2 (66). A periductal infiltrate composed of lymphocytes 
and plasmocytes accompanied by inter and intralobular fibrosis 
is histologically observed. Atrophy of the parenchyma can also 
occur (60). It is possible that some of our patients had IgG4-related 
disease, which might alter the sonographic appearance of the organ. 
In a study of the pancreas, EUS findings were correlated with the 
histopathological findings (29). In our study, the principal findings 
were hyperechoic foci (35%), hyperechoic ductal margins (21%), 
hyperechoic lesions (21%) and a heterogeneous echoic pattern 
(11%). These alterations correspond, respectively, to focal fibrosis, 
periductal fibrosis, bridge fibrosis and edema, characteristics that 
are quite prevalent in AIP.
The pancreatic alterations observed in CD are specifically due 
to the activation of immunocomplexes (4,8,20) since some of these 
patients present with high titers of circulating autoantibodies against 
the exocrine pancreas (17,67-69), which have been directly related to 
the presence of pancreatic insufficiency (17). These autoantibodies 
are believed to induce tropism in exocrine pancreatic acinar cells 
(14). Histologically, B lymphocyte aggregates are observed in 
the pancreatic tissue (20). Pancreatic alterations are believed 
to be less common and less prominent than other extraintestinal 
manifestations of CD because autoantigens come into contact with 
the immune system only outside of the pancreas (67).
 ■ CONCLUSION
In conclusion, the present study showed that in a sample of 51 
patients, 5 (9.8%) presented with three or more EUS abnormalities 
suggestive of chronic pancreatitis, which is significantly different 
than the number observed for the control group. However, none 
of these 5 patients presented with any clinical signs or laboratory 
test results (e.g., fecal elastase levels) indicative of pancreatic 
exocrine insufficiency.
In this group of patients, future studies should be conducted to 
determine whether such morphological abnormalities could evolve 
to induce exocrine or endocrine pancreatic insufficiency and, if 
so, identify the risk factors and determine which patients should 
undergo EUS (8,10,23).
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